Physician profile
Ann C Cabot
NPI 1912018201
$622,197.76
in general payments reported to CMS, 2019-2025
18 companies · $92K in 2025
The $92K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140K · 2020: $76K · 2021: $49K · 2022: $59K · 2023: $105K · 2024: $101K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Consulting Fee: $33K · Travel and Lodging: $9,561 · Food and Beverage: $7,149 · Honoraria: $5,850 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,411.00 |
| Consulting Fee | $32,689.19 |
| Travel and Lodging | $9,560.90 |
| Food and Beverage | $7,149.29 |
| Honoraria | $5,850.00 |
| Education | $272.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $154,423.99 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $126,842.46 | 2021-2025 | |
| Biogen, INC. | $95,269.76 | 2019-2025 | Tysabri, Tysabri, Vumerity |
| Genzyme Corporation | $50,366.66 | 2019-2022 | |
| Genentech USA, INC. | $45,163.79 | 2019-2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $36,884.74 | 2020-2025 | Zeposia |
| Celgene Corporation | $36,408.62 | 2019-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $30,218.98 | 2019-2023 | Kesimpta |
| Novartis Pharma Ag | $13,599.00 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $10,677.00 | 2019-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $8,548.82 | 2019 | |
| Horizon Therapeutics Plc | $6,997.18 | 2023 | Uplizna |
| Genentech, INC. | $6,026.25 | 2023-2025 | Ocrevus |
| Amgen INC. | $377.70 | 2024-2025 | Uplizna |
| Abbvie INC. | $305.59 | 2022-2025 | Qulipta, Ubrelvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65.85 | 2020 | |
| Pfizer INC. | $15.80 | 2023 | |
| Travere Therapeutics, INC. | $5.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Cabot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.